SUPN Supernus Pharmaceuticals Inc

Price (delayed)

$27.66

Market cap

$1.47B

P/E Ratio

14.56

Dividend/share

N/A

EPS

$1.9

Enterprise value

$1.65B

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for ...

Highlights
Supernus Pharmaceuticals's revenue has increased by 35% YoY and by 2.6% from the previous quarter
The gross profit is up by 22% YoY
The stock's price to earnings (P/E) is 24% more than its last 4 quarters average of 11.9 but 20% less than its 5-year quarterly average of 18.5
The quick ratio has contracted by 10% from the previous quarter but it has grown by 3.8% YoY
The EPS has declined by 16% year-on-year and by 10% since the previous quarter
The company's net income fell by 15% YoY and by 10% QoQ

Key stats

What are the main financial stats of SUPN
Market
Shares outstanding
53.15M
Market cap
$1.47B
Enterprise value
$1.65B
Valuations
Price to earnings (P/E)
14.56
Price to book (P/B)
1.87
Price to sales (P/S)
2.57
EV/EBIT
10.44
EV/EBITDA
8.95
EV/Sales
2.89
Earnings
Revenue
$570.95M
EBIT
$158.32M
EBITDA
$184.63M
Free cash flow
$118.12M
Per share
EPS
$1.9
Free cash flow per share
$2.23
Book value per share
$14.82
Revenue per share
$10.77
TBVPS
$21.55
Balance sheet
Total assets
$1.57B
Total liabilities
$787.48M
Debt
$406.53M
Equity
$785.58M
Working capital
$355.8M
Liquidity
Debt to equity
0.52
Current ratio
2.26
Quick ratio
1.93
Net debt/EBITDA
0.99
Margins
EBITDA margin
32.3%
Gross margin
86%
Net margin
17.5%
Operating margin
24.1%
Efficiency
Return on assets
6.6%
Return on equity
13.4%
Return on invested capital
16.4%
Return on capital employed
12.3%
Return on sales
27.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SUPN stock price

How has the Supernus Pharmaceuticals stock price performed over time
Intraday
-1.07%
1 week
1.47%
1 month
4.46%
1 year
33.11%
YTD
9.94%
QTD
-10.17%

Financial performance

How have Supernus Pharmaceuticals's revenue and profit performed over time
Revenue
$570.95M
Gross profit
$491.05M
Operating income
$137.72M
Net income
$100.19M
Gross margin
86%
Net margin
17.5%
The net margin is down by 37% year-on-year and by 13% since the previous quarter
Supernus Pharmaceuticals's revenue has increased by 35% YoY and by 2.6% from the previous quarter
The company's operating margin fell by 34% YoY and by 15% QoQ
The gross profit is up by 22% YoY

Growth

What is Supernus Pharmaceuticals's growth rate over time

Valuation

What is Supernus Pharmaceuticals stock price valuation
P/E
14.56
P/B
1.87
P/S
2.57
EV/EBIT
10.44
EV/EBITDA
8.95
EV/Sales
2.89
The stock's price to earnings (P/E) is 24% more than its last 4 quarters average of 11.9 but 20% less than its 5-year quarterly average of 18.5
The EPS has declined by 16% year-on-year and by 10% since the previous quarter
SUPN's price to book (P/B) is 60% less than its 5-year quarterly average of 4.7 but 5% more than its last 4 quarters average of 1.8
Supernus Pharmaceuticals's equity has increased by 18% YoY and by 4.1% QoQ
The P/S is 48% below the 5-year quarterly average of 5.0 but 4% above the last 4 quarters average of 2.5
Supernus Pharmaceuticals's revenue has increased by 35% YoY and by 2.6% from the previous quarter

Efficiency

How efficient is Supernus Pharmaceuticals business performance
The return on sales has declined by 35% year-on-year and by 12% since the previous quarter
The company's return on equity fell by 31% YoY and by 14% QoQ
The return on assets has declined by 31% year-on-year and by 11% since the previous quarter
SUPN's return on invested capital is down by 12% since the previous quarter

Dividends

What is SUPN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SUPN.

Financial health

How did Supernus Pharmaceuticals financials performed over time
Supernus Pharmaceuticals's total assets is 100% higher than its total liabilities
The quick ratio has contracted by 10% from the previous quarter but it has grown by 3.8% YoY
SUPN's current ratio is up by 9% year-on-year but it is down by 7% since the previous quarter
The debt is 48% smaller than the equity
Supernus Pharmaceuticals's equity has increased by 18% YoY and by 4.1% QoQ
Supernus Pharmaceuticals's debt to equity has decreased by 16% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.